Category

In the News

Phase 3 Trials of Aducanumab Halted

By | Commentary, In the News | No Comments

Contributed by Joshua Grill, PhD, Director of UCI MIND The global research effort to find effective treatments for Alzheimer’s disease has suffered another disappointing setback. Biogen announced today that the company will halt the parallel large Phase 3 trials of the monoclonal antibody against the amyloid beta protein, aducanumab. This treatment was viewed by many to hold tremendous promise. Early results were unprecedented. Patients with Alzheimer’s disease who were treated with aducanumab showed significant reduction in amyloid burden in the brain, which appeared to slow disease progression. The results were based on a small number of participants, however, and were not…

Read More

Forgetful Yet Unforgettable: The Legacy of an Alzheimer’s Patient

By | Commentary, In the News | No Comments

In an interview with UCI undergraduate students, Chelsea Cox, Associate Director of Eduction for UCI MIND, shares her personal journey with Alzheimer’s disease, her perspective on care and research, and how people – young and old – can get involved in the cause. “…No one should have to spend their final days that way. This experience is what motivated me to get involved in Alzheimer’s research and education. So that hopefully, one day, other people don’t have to go through what my family went through.” Read the full interview on Medium >

Read More

FDA issues warning to dietary supplements making unproven claims

By | Commentary, In the News | No Comments

On February 11, the FDA issued a statement and 12 warning letters related to an aggressive change in the agency’s regulation of dietary supplements. The statement was outlined in the New York Times. The main objective of the new approach is enhanced protection of consumers from mislabeled and unproven claims about treatment of disease. At the core of the problem are a number of companies that specifically target people with Alzheimer’s disease and people who are concerned about developing Alzheimer’s disease. A list of the companies receiving warning letters, as well as links to the letters, can be found here.

Read More

Leslie Thompson gets $6 million CIRM grant to advance Huntington’s disease treatments

By | In the News | No Comments

  UCI News, January 30, 2019 – “Leslie Thompson of the Sue & Bill Gross Stem Cell Research Center and UCI MIND has been awarded $6 million by the California Institute for Regenerative Medicine to continue her CIRM-supported efforts to create stem cell treatments for Huntington’s disease. The funding will allow the Thompson lab to conduct the late-stage testing needed to apply to the U.S. Food and Drug Administration for permission to start a clinical trial in people. The therapy involves transplanting stem cells that have been turned into neural stem cells and shown to improve the function of brain cells in…

Read More